Online inquiry

IVTScrip™ mRNA-Human ARPP19, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK22073MR)

This product GTTS-WK22073MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the ARPP19 protein. This product can be used in Regulatory T (Treg) cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001306191.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 10776
UniProt ID P56211
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARPP19, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WK22073MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK26826MR IVTScrip™ mRNA-Human ARID4B, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARID4B
GTTS-WK9561MR IVTScrip™ mRNA-Human ADORA2B, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADORA2B
GTTS-WK10741MR IVTScrip™ mRNA-Human ADGRG1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADGRG1
GTTS-WK14604MR IVTScrip™ mRNA-Human ANKRD18A, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD18A
GTTS-WK13097MR IVTScrip™ mRNA-Human ADAM9, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADAM9
GTTS-WK26837MR IVTScrip™ mRNA-Human ARL16, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARL16
GTTS-WK23788MR IVTScrip™ mRNA-Human ARHGAP23, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARHGAP23
GTTS-WK21226MR IVTScrip™ mRNA-Human ANKRD44, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANKRD44
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW